Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFA vs up to three modified natural cycles in poor responders undergoing ART
2023-509094-23-00Phase 4Authorised
- Sponsor
- Ghent University Hospital
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of corifollitropin alfa in hypofertility (2 arms), sponsored by Ghent University Hospital. Primary endpoint: At least one good quality blastocyst after ART. Planned start Jun 2024; status: authorised.
02
Drugs
corifollitropin alfa
03
Conditions
hypofertility
Beyond the preview
Go deeper on 2023-509094-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509094-23-00.